allogeneic anti-CD20 CAR T cells LUCAR-20SP
Term · Oncology and biomedicine · MLC-T-ONC-009813
A preparation of donor-derived T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) cluster of differentiation 20 (CD20), with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic anti-CD20 CAR T cells LUCAR-20SP specifically recognize and kill CD20-expressing tumor cells. CD20, a non-glycosylated cell surface phosphoprotein, is a B-cell specific cell surface antigen expressed in B-cell lineage malignancies.
| Identifier | MLC-T-ONC-009813 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | allogeneic anti-CD20 CAR-T cells LUCAR-20SP |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-009813",
"term": "allogeneic anti-CD20 CAR T cells LUCAR-20SP",
"field": "Oncology and biomedicine",
"definition": "A preparation of donor-derived T lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) cluster of differentiation 20 (CD20), with potential immunostimulating and antineoplastic activities. Upon administration, allogeneic anti-CD20 CAR T cells LUCAR-20SP specifically recognize and kill CD20-expressing tumor cells. CD20, a non-glycosylated cell surface phosphoprotein, is a B-cell specific cell surface antigen expressed in B-cell lineage malignancies.",
"synonyms": [
"allogeneic anti-CD20 CAR-T cells LUCAR-20SP"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/allogeneic-anti-cd20-car-t-cells-lucar-20sp/"
}
Record 698 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.